title: Systemic delivery of stable siRNA-encapsulating lipid vesicles: optimization, biodistribution, and tumor suppression.
abstract: Lipid-based nanoparticles are considered as promising candidates for delivering siRNA into the cytoplasm of targeted cells. However, in vivo efficiency of these nanoparticles is critically dependent on formulation strategies of lipid-siRNA complexes. Adsorption of serum proteins to lipid-siRNA complexes and its charge determine siRNA degradation and serum half-life, thus significantly altering the bioavailability of siRNA. To address these challenges, we developed a formulation comprising dihydroxy cationic lipid, N,N-di-n-hexadecyl-N,N-dihydroxyethylammonium chloride (DHDEAC), cholesterol, and varying concentrations of 1,2-distearoryl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol-2000)] (DSPE-PEG 2000). Using an ethanol dilution method, addition of these lipids to siRNA solution leads to formation of stable and homogeneous population of siRNA-encapsulated vesicles (SEVs). Biodistribution of these SEVs, containing 5 mol % of DSPE-PEG 2000 in xenograft mice, as monitored by live animal imaging and fluorescence microscopy, revealed selective accumulation in the tumor. Remarkably, four intravenous injections of the modified vesicles with equimolar amounts of siRNA targeting ErbB2 and AURKB genes led to significant gene silencing and concomitant tumor suppression in the SK-OV-3 xenograft mouse model. Safety parameters as evaluated by various markers of hepatocellular injury indicated the nontoxic nature of this formulation. These results highlight improved pharmacokinetics and effective in vivo delivery of siRNA by DHDEAC-based vesicles.
authors.affiliation: CSIR-Centre for Cellular and Molecular Biology , Uppal Road, Hyderabad 500007, Andhra Pradesh, India.
authors.forename: Ghulam Hassan
authors.initials: GH
authors.lastname: Dar
authors.forename: Vijaya
authors.initials: V
authors.lastname: Gopal
authors.forename: N Madhusudhana
authors.initials: NM
authors.lastname: Rao
mesh_terms: D000818:Animals; D002784:Cholesterol / Q000737:chemistry; D020868:Gene Silencing; D006367:HeLa Cells; D006801:Humans; D008055:Lipids / Q000737:chemistry*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D046529:Microscopy, Electron, Transmission; D034741:RNA, Small Interfering / Q000008:administration & dosage / Q000737:chemistry*; D023041:Xenograft Model Antitumor Assays
chemical_list: D008055:Lipids; D034741:RNA, Small Interfering; D002784:Cholesterol
keywords: DSPE-PEG (2000); RNAi therapeutics; cationic lipid; cholesterol; gene silencing; pharmacokinetics; siRNA delivery; xenograft tumor